WO2023222332 - DIPHENYL UREAS FOR THE TREATMENT OF VIRAL INFECTIONS
National phase entry is expected:
Publication Number
WO/2023/222332
Publication Date
23.11.2023
International Application No.
PCT/EP2023/060613
International Filing Date
24.04.2023
Title **
[English]
DIPHENYL UREAS FOR THE TREATMENT OF VIRAL INFECTIONS
[French]
URÉES DE DIPHÉNYLE POUR LE TRAITEMENT D'INFECTIONS VIRALES
Applicants **
MERCK PATENT GMBH
Frankfurter Strasse 250
64293 Darmstadt, DE
Inventors
BETZ, Ulrich
c/o Merck Healthcare KGaA
Frankfurter Strasse 250
64293 DARMSTADT, DE
LINDEMANN, Sven
c/o Merck KGaA
Frankfurter Strasse 250
64293 DARMSTADT, DE
Priority Data
22173527.7
16.05.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1296 | |
| EPO | Filing, Examination | 5348 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 10520 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention encompasses diphenyl urea selected but not limited from the group of compounds 1 -7 for use in the treatment of virus and coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.[French]
La présente invention concerne une urée de diphényle sélectionnée, mais sans s'y limiter, dans le groupe des composés 1-7 pour une utilisation dans le traitement d'infections virales et à coronavirus, y compris la COVID-19, seule ou en combinaison avec un ou plusieurs agents thérapeutiques supplémentaires.